Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 158, Issue 5 PART I, 1998, Pages 1388-1395

  Ziegler, James W ^a   Ivy, D Dunbar ^b   Wiggins, James W ^b   Kinsella, John P ^b   Clarke, William R ^b   Abman, Steven H ^b  

^a RHODE ISLAND HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; CYCLIC GMP PHOSPHODIESTERASE; DIPYRIDAMOLE; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR;

ADOLESCENT; ADULT; AORTA PRESSURE; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART INDEX; HUMAN; HYPOXIA; INHALATIONAL DRUG ADMINISTRATION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; MALE; PRESSOR RESPONSE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYSTEMIC VASCULAR RESISTANCE; VASODILATATION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANOXIA; AORTA; BLOOD PRESSURE; BRONCHODILATOR AGENTS; CARDIAC OUTPUT; CHILD; CHILD, PRESCHOOL; CYCLIC GMP; DIPYRIDAMOLE; FEMALE; HEART CATHETERIZATION; HUMANS; HYPERTENSION, PULMONARY; INFANT; MALE; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; PULMONARY ARTERY; PULMONARY CIRCULATION; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 0031762610     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.158.5.9710117     Document Type: Article

References (57)

1. Ignarro, L. J. 1989. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ. Res. 1:1-21.
2. Stamler, J. S., E. Loh, M. A. Roddy, K. E. Currie, and M. A. Creager. 1994. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 89:2035-2040.
3. Celermajer, D. S., C. Dollery, M. Burch, J. E. Deanfield. 1994. Role of endothelium in the maintenance of low pulmonary vascular tone in normal children. Circulation 89:2041-2044.
4. Arnold, W. P., C. K. Mittal, S. Katsuki, and F. Murad. 1977. Nitric oxide activates guanylate cyclase and increases guanosine 3′5′-cyclic monophosphate levels in various tissue preparations. Proc. Natl. Acad, Sci. U.S.A. 74:3203-3207.
5. Griffith, T. M., D. H. Edwards, M. J. Lewis, and A. H. Henderson. 1985. Evidence that cyclic guanosine monophosphate (cGMP) mediates endothelium-dependent relaxation. Eur. J. Pharmacol. 112:195-202.
6. Collins, P., T. M. Griffin, A. H. Henderson, and M. J. Lewis. 1986. Endothelium-derived relaxing factor alters calcium fluxes in rabbit aorta: a cyclic guanosine monophosphate-mediated effect. J. Physiol. 381:427-437.
7. Waldman, S. A., and F. Murad. 1988. Biochemical mechanisms underlying vascular smooth muscle relaxation: the guanylate cyclase-cyclic GMP system. J. Cardiovasc. Pharmacol. 12:S115-S118.
8. Thomas, M. K., S. H. Francis, and J. D. Corbin. 1990. Characterization of a purified bovine lung cGMP-binding cGMP phophodiesterase. J. Biol. Chem. 265:14964-14970.
9. Lugnier, C., P. Schoeffter, A. Le Bec, E. Strouthou, and J. C. Stockt. 1986. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine, and rat aorta. Biochem. Pharmacol. 35:1743-1751.
10. Beavo, J., and D. H. Reifsnyder. 1990. Primary sequence of cyclic nucleotide phosphodiesteras isozymes and the design of selective inhibitors. Trends Pharmacol. Sci. 11:150-155.
11. Celermajer, D. S., S. Cullen, and J. E. Deanfield. 1993. Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation 87:440-446.
12. Giaid, A., and D. Saleh. 1995. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 333:214-221.
13. McQueston, J. A., J. P. Kinsella, D. D. Ivy, I. F. McMurtry, and S. H. Abman. 1995. Chronic pulmonary hypertension in utero impairs endothelium-dependent vasodilation. Am. J. Physiol. 268:H288-H294.
14. Cohen, A. H., K. Hanson, K. Morris, B. Fouty, I. F. McMurtry, W. Clarke, and D. M. Rodman. 1996. Inhibition of cGMP-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J. Clin. Invest. 97:172-179.
15. Scherrer, U., L. Vollenweider, A. Delabays, M. Savcic, U. Eichenberger, G. R. Kleger, A. Fikrle, P. E. Ballmer, P. Nicod, and P. Bartsch. 1996. Inhaled nitric oxide for high-altitude pulmonary edema. N. Engl. J. Med. 334:624-629.
16. Kinsella, J. P., J. A. McQueston, A. A. Rosenberg, and S. H. Abman. 1992. Hemodynamic effects of exogenous nitric oxide in ovine transitional pulmonary circulation. Am. J. Physiol 263:H875-H880.
17. Frostell, C., M. D. Fratacci, J. C. Wain, R. Jones, and W. M. Zapol. 1991. Inhaled nitric oxide, a selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 83:2038-2047.
18. Roberts, J. D., T. Y. Chen, N. Kawai, J. Wain, P. Dupuy, A. Shimouchi, K. Bloch, D. Polaner, and W. M. Zapol. 1993. Inhaled nitric oxide reverses pulmonary vasoconstriction in the hypoxic and acidotic newborn lamb. Circ. Res. 72:246-254.
19. Pepke-Zaba, J., T. W. Higenbottam, A. T. Dinh-Xuan, D. Stone, and J. Wallwork. 1991. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet 338:1173-1174.
20. Roberts, J. D., D. M. Polaner, P. Lang, and W. M. Zapol. 1992. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 340:818-819.
21. Kinsella, J. P., S. R. Neish, E. Shaffer, and S. H. Abman. 1992. Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 340:819-820.
22. Roberts, J. D., P. Lang, L. M. Bigatello, G. J. Vlahakes, and W. M. Zapol. 1993. Inhaled nitric oxide in congenital heart disease. Circulation 87:447-453.
23. Wessel, D. L., I. Adatia, T. M. Giglia, J. E. Thompson, and T. J. Kulik. 1993. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation 88:2128-2138.
24. Braner, D. A. V., J. R. Fineman, R. Chang, and S. J. Soiffer. 1993. M & B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am. J. Physiol. 264:H252-H258.
25. McMahon, T. J., L. J. Ignarro, and P. J. Kadowitz. 1993. Influence of zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. J. Appl. Physiol. 74:1704-1711.
26. Ichinose, F., C. Adrie, W. E. Hurford, and W. M. Zapol. Prolonged pulmonary vasodilator action of inhaled nitric oxide by zaprinast in awake lambs. 1995. J. Appl. Physiol. 78:1288-1295.
27. Thusu, K. G., F. C. Morin, J. A. Russell, and R. H. Steinhom. 1995. The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide. Am. J. Respir. Crit. Care Med. 152:1605-1610.
28. Fitzgerald, G. A. 1987. Dipyridamole. N. Engl. J. Med. 316:1247-1256.
29. Rosenkrantz, J. G., F. P. Lynch, and J. H. K. Vogel. 1972. Hypoxic pulmonary hypertension: its modification by dipyridmole. J. Surg. Res. 12:330-333.
30. Keith, I. M., J. A. Will, R. J. Huxtalbe, and K. Weir. 1987. Anti-platelet agents reduce morphological changes of chronic hypoxic pulmonary hypertension. Histol. Histopathol. 2:203-206.
31. Ziegler, J. W., D. D. Ivy, J. J. Fox, J. P. Kinsella, W. R. Clarke, and S. H. Abman. 1995. Dipyridamole, a cGMP phosphodiesterase inhibitor, causes pulmonary vasodilation in the ovine fetus. Am. J. Physiol. 269:H473-H479.
32. Skimming, J. W., V. G. DeMarco, and S. Cassin. 1996. Dipyridamole causes vasodilation primarily via A2 adenosine receptor independent mechanisms (abstract). Pediatr. Res. 39:37A.
33. Ziegler, J. W., D. D. Ivy, J. J. Fox, J. P. Kinsella, W. R. Clarke, and S. H. Abman. 1998. Dipyridamole potentiates acetylcholine and nitric oxide induced pulmonary vasodilation in the ovine fetus. Am. J. Respir. Crit. Care Med. 157:1104-1110.
34. Dukarm, R. C., F. C. Morin III, J. A. Russell, and R. H. Steinhorn. 1996. Effects of the phosphodiesterase inhibitor dipyridamole on inhaled nitric oxide in newborn lambs with persistent pulmonary hypertension (abstract). Pediatr. Res. 39:331A.
35. Bull, H., H. R. L. Fret, F. H. Jordaens, and A. G. Herman. 1991. Dipyridamole potentiates the anti-aggregating and vasodilator activity of nitric oxide. Eur. I. Phamacol. 199:1-8.
36. Crimi, N., F. Palermo, R. Oliveri, C. Maccarrone, B. Palermo, C. Vancheri, R. Polosa, and A. Mistretta. 1988. Enhancing effect of dipyridamole inhalation on adenosine-induced bronchospasm in asthmatic patients. Allergy 43:179-183.
37. Nienaber, C. A., R. P. Spielmann, and G. Hausdorf. 1988. Dipyridamolethallium-201 tomography documenting improved myocardial perfusion with therapy in Kawasaki disease. Am. Heart J. 116:1575-1579.
38. Kondo, C., M. Hiroe, T. Nakanishi, and A. Takao. 1989. Detection of coronary artery stenosis in children with Kawasaki disease. Circulation 80:615-624.
39. Matsumura, K., Y. Okuda, Y. Ito, T. Hirano, K. Takeda, and N. Yamaguchi. 1988. Coronary angiography of Kawasaki disease with the coronary vasodilator dipyridamole: assessment of distensibility of affected coronary arterial wall. Angiology 2:141-147.
40. Fullerton, D. A., J. Jaggers, F. Piedalue, F. L. Grover, and R. C. McIntyre, Jr. 1997. Effective control of refractory pulmonary hypertension after cardiac operations. J. Thorac. Cardiovasc. Surg. 113:363-370.
41. Loh, E., J. S. Stamler, J. M. Hare, J. Loscalzo, and W. S. Colucci. 1994. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation 90:2780-2785.
42. Semigran, M. J., B. A. Cockrill, R. Kacmarek, B. T. Thompson, and W. M. Zapol. 1994. Hemodynamic effects of inhaled nitric oxide in heart failure. J. Am. Coll. Cardiol. 24:982-988.
43. Bocchi, E. A., F. Bacal, J. O. Auler Junior, G. Bellotti, and F. Pileggi. 1994. Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure. Am. J. Cardiol. 74:70-72.
44. Ivy, D. D., J. P. Kinsella, J. W. Ziegler, and S. H. Abman. 1998. Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease. J. Thorac. Cardiovasc. Surg. 115:875-882.
45. Mlczoch, J., E. K. Weir, and R. F. Grover. 1977. Inhibition of hypoxic pulmonary vasoconstriction by dipyridamole is not platelet mediated. Can. J. Physiol. Pharmacol. 55:448-451.
46. Doyle, J. T., J. S. Wilson, and J. V. Warren. 1952. The pulmonary vascular response to short-term hypoxia in human subjects. Circulation 5:263-270.
47. Westcott, R. N., N. O. Fowler, R. C. Scott, V. D. Hauenstein, and J. McGuire. 1951. Anoxia and human pulmonary vascular resistance. J. Clin. Invest. 30:957-970.
48. Fishman, A. P., H. W. Fritts, and A. Cournand. 1960. Effects of acute hypoxia and exercise on the pulmonary circulation. Circulation 22:204-215.
49. James, L. S., and R. D. Rowe. 1957. The pattern of response of pulmonary and systemic arterial pressures in newborns and older infants to short periods of hypoxia. J. Pediatr. 51:5-11.
50. Fasules, J. W., J. W. Wiggins, and R. R. Wolfe. 1985. Increased lung vasoreactivity in children from Leadville, Colorado after recovery from high-altitude pulmonary edema. Circulation 72:957-962.
51. Jones, T. K., J. W. Wiggins, and R. R. Wolfe. 1982. Symptomatic high altitude pulmonary hypertension of infancy (abstract). Circulation 66(Suppl. 2):II-48.
52. Abman, S. H., R. R. Wolfe, F. J. Accurso, B. L. Koops, C. M. Bowman, and J. W. Wiggins. 1985. Pulmonary vascular response to oxygen in infants with severe bronchopulmonary dysplasia. Pediatrics 75:80-84.
53. Khoury, G. H., and C. R. Hawes. 1963. Primary pulmonary hypertension in children living at high altitude. J. Pediatr. 62:177-185.
54. Johns, R. A., J. M. Linden, and M. J. Peach. 1989. Endothelium-dependent relaxation and cyclic GMP accumulation in rabbit pulmonary artery are selectively impaired by moderate hypoxia. Circ. Res. 65:1508-1515.
55. Kinsella, J. P., F. Torielli, J. W. Ziegler, D. D. Ivy, and S. H. Abman. 1995. Dipyridamole augmentation of the response to inhaled NO. Lancet 346:647-648.
56. al-Alaiyan, S., and A. al-Omran. 1996. The use of phosphodiesterase inhibitor (dipyridamole) to wean from inhaled nitric oxide. Intensive Care Med. 22:1093-1095.
57. Buga, G. M., J. M. Griscavage, N. E. Rogers, and L. J. Ignarro. 1993. Negative feedback regulation of endothelial cell function by nitric oxide. Circ. Res. 73:808-812.